48,453
edits
Difference between revisions of "Prostate cancer"
Jump to navigation
Jump to search
m
vauthors
m (vauthors) |
|||
| (One intermediate revision by one other user not shown) | |||
| Line 242: | Line 242: | ||
===Situations where prostate adenocarcinoma may be missed=== | ===Situations where prostate adenocarcinoma may be missed=== | ||
Key reasons for false negative prostate samples<ref>{{cite journal | | Key reasons for false negative prostate samples<ref>{{cite journal |authors=Yang C, Humphrey PA |title=False-Negative Histopathologic Diagnosis of Prostatic Adenocarcinoma |journal=Arch. Pathol. Lab. Med. |volume=144 |issue=3 |pages=326–334 |date=March 2020 |pmid=31729886 |doi=10.5858/arpa.2019-0456-RA |url=}}</ref>: | ||
*Tissue artefacts (try levels and/or IHC): | *Tissue artefacts (try levels and/or IHC): | ||
**Crush artefact | **Crush artefact | ||
| Line 256: | Line 256: | ||
**[[PIN-like adenocarcinoma]] | **[[PIN-like adenocarcinoma]] | ||
**Microcystic adenocarcinoma | **Microcystic adenocarcinoma | ||
*Single cells of Gleason 5 adenocarcinoma (missed or mistaken for lymphocytes; try IHC) | *Single cells of Gleason 5 adenocarcinoma (missed or mistaken for lymphocytes; try IHC for cytokeratins, prostatic and/or hematologic markers) | ||
*Treatment effect (check clinical information and look for treatment effect in benign glands) | *Treatment effect (check clinical information and look for treatment effect in benign glands) | ||